QH101
/ Beijing Qinghui Liannuo Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 19, 2026
QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=7 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P1 trial • Oncology • Solid Tumor
May 07, 2026
Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.
(clinicaltrials.gov)
- P1/2 | N=24 | Recruiting | Sponsor: Chinese PLA General Hospital
New P1/2 trial • Hematological Malignancies • Oncology • Solid Tumor
December 30, 2025
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
(clinicaltrials.gov)
- P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
IO biomarker • New P1/2 trial • Oncology • Solid Tumor
August 21, 2025
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Anhui Provincial Hospital
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 4
Of
4
Go to page
1